Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Dec;44(8):817-28.
doi: 10.3109/07853890.2012.665471. Epub 2012 Mar 16.

The molecular basis of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum

Affiliations
Free PMC article
Review

The molecular basis of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum

Tim Van Langenhove et al. Ann Med. 2012 Dec.
Free PMC article

Abstract

There is increasing evidence that frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS) represent a continuum of neurodegenerative diseases. FTLD is complicated by ALS in a significant proportion of patients, and neuropsychological studies have demonstrated frontotemporal dysfunction in up to 50% of ALS patients. More recently, advances in neuropathology and molecular genetics have started to disclose the biological basis for the observed clinical concurrence. TDP-43 and FUS have been discovered as key pathological proteins in both FTLD and ALS. The most recent discovery of a pathological hexanucleotide repeat expansion in the gene C9orf72 as a frequent cause of both FTLD and ALS has eventually confirmed the association of these two at first sight distinct neurodegenerative diseases. Mutations in the TARDBP, FUS, and VCP genes had previously been associated with different phenotypes of the FTLD-ALS spectrum, although in these cases one end of the spectrum predominates. Whilst on the one hand providing evidence for overlap, these discoveries have also highlighted that FTLD and ALS are etiologically diverse. In this review, we review the recent advances that support the existence of an FTLD-ALS spectrum, with particular emphasis on the molecular genetic aspect.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
A: FTLD and ALS form a clinical disease continuum. B: Molecular relationships between FTLD and ALS. Pathological proteins are indicated in blue, causal genes in yellow. Full lines indicate strong correlations; dotted lines represent putative correlations. Correlations between genes and pathological proteins are indicated by light gray lines.
Figure 2.
Figure 2.
TDP-43 proteinopathy in FTLD. Ubiquitin and TDP-43 immunohistochemistry of sections from the superficial frontal cortex (FCx) and temporal cortex (TCx) of a patient with a VCP mutation (176). Frequent intranuclear inclusions (arrow-heads) are seen that stain positive for ubiquitin and TDP-43.

Similar articles

Cited by

References

    1. Ringholz GM, Appel SH, Bradshaw M, Cooke NA, Mosnik DM, Schulz PE. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology. 2005;65:586–90. - PubMed
    1. Lomen-Hoerth C, Murphy J, Langmore S, Kramer JH, Olney RK, Miller B. Are amyotrophic lateral sclerosis patients cognitively normal? Neurology. 2003;60:1094–7. - PubMed
    1. Harvey RJ, Skelton-Robinson M, Rossor MN. The prevalence and causes of dementia in people under the age of 65 years. J Neurol Neurosurg Psychiatr. 2003;74:1206–9. - PMC - PubMed
    1. Knopman DS, Petersen RC, Edland SD, Cha RH, Rocca WA. The incidence of frontotemporal lobar degeneration in Rochester, Minnesota, 1990 through 1994. Neurology. 2004;62:506–8. - PubMed
    1. Mercy L, Hodges JR, Dawson K, Barker RA, Brayne C. Incidence of early-onset dementias in Cambridgeshire, United Kingdom. Neurology. 2008;71:1496–9. - PubMed

Publication types

MeSH terms